Published

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Scientific reports
Date: 2023-08-22
Source: PubMed
DOI: 10.1038/s41598-023-40856-5
PubMed: 37608057

Authors

Zeifman RJ Kettner H Pagni BA Mallard A Roberts DE Erritzoe D Ross S Carhart-Harris RL

Watch author

Derived topics and classifications

psilocybin Mystical Experience Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development2026-07-03 Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.2023-08-22

Related papers

Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping reviewJournal of Psychedelic Studies · 2026-03-09 Identifying Three Psilocybin Use Patterns by Frequency and Quantity.Journal of studies on alcohol and drugs · 2025-05-01 Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitionersJournal of Psychedelic Studies · 2025-02-05 Psychedelic use and psychological flexibility: The role of meaningful intention and decenteringJournal of Psychedelic Studies · 2024-08-16 Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.ClinicalTrials.gov · 2023-12-26 The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic ReviewJournal of Sociology Psychology & Religious Studies · 2023-11-06 Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020Journal of Medical and Health Studies · 2021-12-31 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10